ATYR PHARMA INC (ATYR) Stock Fundamental Analysis

NASDAQ:ATYR • US0021202025

0.9942 USD
+0.01 (+1.14%)
At close: Feb 18, 2026
0.9799 USD
-0.01 (-1.44%)
After Hours: 2/18/2026, 8:15:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

ATYR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While ATYR seems to be doing ok healthwise, there are quite some concerns on its profitability. ATYR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ATYR had negative earnings in the past year.
  • ATYR had a negative operating cash flow in the past year.
  • In the past 5 years ATYR always reported negative net income.
  • ATYR had a negative operating cash flow in each of the past 5 years.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • ATYR has a worse Return On Assets (-70.44%) than 62.38% of its industry peers.
  • Looking at the Return On Equity, with a value of -93.63%, ATYR is in line with its industry, outperforming 47.79% of the companies in the same industry.
Industry RankSector Rank
ROA -70.44%
ROE -93.63%
ROIC N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • ATYR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ATYR has been increased compared to 1 year ago.
  • The number of shares outstanding for ATYR has been increased compared to 5 years ago.
  • The debt/assets ratio for ATYR has been reduced compared to a year ago.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ATYR has an Altman-Z score of -7.15. This is a bad value and indicates that ATYR is not financially healthy and even has some risk of bankruptcy.
  • ATYR has a worse Altman-Z score (-7.15) than 65.07% of its industry peers.
  • ATYR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • ATYR has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.15
ROIC/WACCN/A
WACC8.65%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • ATYR has a Current Ratio of 5.93. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
  • ATYR has a better Current ratio (5.93) than 61.80% of its industry peers.
  • ATYR has a Quick Ratio of 5.93. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.93, ATYR is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.93
Quick Ratio 5.93
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.70%, which is quite good.
  • Looking at the last year, ATYR shows a very negative growth in Revenue. The Revenue has decreased by -19.15% in the last year.
  • ATYR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.05% yearly.
EPS 1Y (TTM)11.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
Revenue 1Y (TTM)-19.15%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.14% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 298.77% on average over the next years. This is a very strong growth
EPS Next Y1.68%
EPS Next 2Y12.39%
EPS Next 3Y11.43%
EPS Next 5Y22.14%
Revenue Next Year-40.54%
Revenue Next 2Y958.09%
Revenue Next 3Y560.12%
Revenue Next 5Y298.77%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATYR. In the last year negative earnings were reported.
  • Also next year ATYR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.39%
EPS Next 3Y11.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ATYR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATYR PHARMA INC

NASDAQ:ATYR (2/18/2026, 8:15:02 PM)

After market: 0.9799 -0.01 (-1.44%)

0.9942

+0.01 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners63.43%
Inst Owner ChangeN/A
Ins Owners1.41%
Ins Owner Change4.28%
Market Cap97.42M
Revenue(TTM)190.00K
Net Income(TTM)-75.12M
Analysts73.75
Price Target6.48 (551.78%)
Short Float %21.16%
Short Ratio9.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.87%
Min EPS beat(2)-38.81%
Max EPS beat(2)-16.94%
EPS beat(4)2
Avg EPS beat(4)-5.39%
Min EPS beat(4)-38.81%
Max EPS beat(4)21.92%
EPS beat(8)4
Avg EPS beat(8)-2.16%
EPS beat(12)8
Avg EPS beat(12)7.83%
EPS beat(16)9
Avg EPS beat(16)2.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.09%
Revenue NQ rev (1m)-14.28%
Revenue NQ rev (3m)28.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-90.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 512.75
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.44%
ROE -93.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -21.19%
Cap/Sales 37.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.93
Quick Ratio 5.93
Altman-Z -7.15
F-Score3
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)476.17%
Cap/Depr(5y)300.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.04%
EPS Next Y1.68%
EPS Next 2Y12.39%
EPS Next 3Y11.43%
EPS Next 5Y22.14%
Revenue 1Y (TTM)-19.15%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%N/A
Revenue Next Year-40.54%
Revenue Next 2Y958.09%
Revenue Next 3Y560.12%
Revenue Next 5Y298.77%
EBIT growth 1Y-15.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.35%
EBIT Next 3Y-1%
EBIT Next 5Y-13.08%
FCF growth 1Y-66.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.44%
OCF growth 3YN/A
OCF growth 5YN/A

ATYR PHARMA INC / ATYR FAQ

What is the ChartMill fundamental rating of ATYR PHARMA INC (ATYR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATYR.


What is the valuation status for ATYR stock?

ChartMill assigns a valuation rating of 0 / 10 to ATYR PHARMA INC (ATYR). This can be considered as Overvalued.


How profitable is ATYR PHARMA INC (ATYR) stock?

ATYR PHARMA INC (ATYR) has a profitability rating of 0 / 10.


Can you provide the financial health for ATYR stock?

The financial health rating of ATYR PHARMA INC (ATYR) is 4 / 10.